Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development stage company, is focused on safer, more effective, less invasive and more economical oncology and dermatology therapies. Currently, the company is conducting Phase 2 clinical trials of their proprietary drugs designed to treat psoriasis, metastatic melanoma, and atopic dermatitis. Provectus has developed multiple intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For further information, visit the Company’s web site at www.pvct.com.
- 17 years ago
QualityStocks
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Secures Up to $100 Million in Project Financing for 97 MW U.S. Solar Portfolio
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has…
-
QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary Bollinger Delivers EV Truck to LES Ecology Center
Mullen Automotive (NASDAQ: MULN) announced that its subsidiary, Bollinger Motors, has delivered a Bollinger B4…
-
QualityStocksNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) CEO to Present Live via Skyline Signature Series on May 7
FingerMotion (NASDAQ: FNGR), a mobile services, data and technology company, announced that CEO Martin J.…